Nancy F.Verified buyer
Jun 22, 2026
★★★★★
Shipping
I received it faster than I expected and the purity was what it claimed on the site. Was impressed with the ordering process.
Research summary
GLP3-R — clinical & mechanistic profile
GLP3-R (Retatrutide/LY3437943) is a first-in-class triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 3 TRIUMPH-4 trial (2026) showed 28.7% weight loss at 12mg/68 weeks — the highest ever reported. Additional Phase 3 data shows A1C reductions of 1.7-2.0%, up to 100% liver fat reduction in MASLD, and 14 mmHg systolic BP reduction. FDA approval projected for 2027.
Research status
clinical investigational
Molecular weight
4624.2 g/mol
Studied applications
- •Triple receptor agonism: first compound to activate GIP, GLP-1, and glucagon receptors in a single molecule
- •Phase 2 results: achieved 24.2% mean weight loss at highest dose (12 mg) over 48 weeks—highest reported for any anti-obesity medication
- •Phase 3 trials: multiple ongoing studies including TRIUMPH program for obesity, T2D, CKD, osteoarthritis, and cardiovascular outcomes
- •Glucagon component: adds energy expenditure and hepatic fat reduction beyond dual agonists
- •No plateau observed: weight loss continued throughout 48-week Phase 2 study without leveling off
Mechanisms of action
- •GLP-1 receptor agonism: glucose-dependent insulin secretion, appetite suppression, delayed gastric emptying
- •GIP receptor agonism: enhanced insulin sensitivity, potentiation of GLP-1 effects, improved lipid handling
- •Glucagon receptor agonism: modulated metabolic research endpoints expenditure, enhanced hepatic fat oxidation, thermogenesis
- •Synergistic metabolic effects: the three pathways produce additive/synergistic weight loss beyond dual agonists
- •Potential NASH/MASH benefit: glucagon component may specifically target hepatic steatosis
Research constraints & safety notes
- •Investigational compound—NOT yet FDA approved for any indication
- •Phase 3 trials ongoing through 2025-2026 with results pending
- •Glucagon component requires careful glycemic management in T2D patients
- •Long-term safety data still being collected
- •Not available as approved medication; only in clinical trials or as research compound
Peer-reviewed references
- Jastreboff AM, et al. — Phase 2 obesity trial (NEJM 2023)PMID: 37351564View
- GLP3-R Phase 2 diabetes trial resultsPMID: 38587237View
- Triple agonist mechanism reviewPMID: 37840095View
- PMC12026077 — GLP3-R GLP-1/GIP/glucagon mechanism comprehensive review
- ADA 2024 — New glp3-r Phase 3 TRIUMPH program data presentations
For research use only. This summary is a research-scientific overview compiled from peer-reviewed sources. It is not medical advice and is not intended for human or veterinary consumption.
Related products